TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Will Veterans Engage in Prevention After HRA-guided Shared Decision Making?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be included in the study, patients must meet the following:~* enrolled in primary care at the Durham or Ann Arbor Health Care Systems~* have one modifiable risk factor identified by a healthy living assessment (physical inactivity, overweight or obese by BMI, or tobacco user)~Exclusion Criteria:~Individuals will be excluded if they have any of the following:~* have been hospitalized for a stroke, myocardial infarction or coronary artery revascularization in the past three months~* have an active diagnosis of psychosis~* have any other health condition they feel would impede participation in the study~* reside in a nursing home~* are severely impaired in hearing or speech, so that they cannot respond to telephone calls~* have significant cognitive or memory impairment~* do not have access to a telephone~* are participating in another prevention intervention study~* are already enrolled in a formal prevention service

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Primary care phone-based prevention coaching using shared decision making following a Healthy Living Assessment
- Control (Type: NO_INTERVENTION): Usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alemtuzumab to Treat Severe Aplastic Anemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Relapsed severe aplastic anemia after initial hematologic response to a prior course of h-ATG or r-ATG based immunosuppression~Or~Refractory severe aplastic anemia not responding to both horse-ATG and rabbit ATG-based immunosuppression~The criteria for severe aplastic anemia are two of the three criteria:~* Absolute neutrophil count less than or equal to 500 /mm(3)~* Platelets to less than or equal to 20,000/mm(3)~* Absolute reticulocyte count less than 60,000 /microL~Age greater than or equal to 2 years old and greater than 12 kg~Prospective subjects or their parent(s)/responsible guardian(s) must be able to comprehend and be willing to sign an informed consent.~EXCLUSION CRITERIA:~Known Diagnosis of Fanconi's anemia~Evidence of a clonal disorder on cytogenetics. In the refractory disease setting, prospective subjects with super severe neutropenia (ANC less than 200 /microL) will not be excluded if results of cytogenetics are not available or pending.~Infection not adequately responding to appropriate therapy~HIV positivity~Failure to discontinue the herbal supplements Echinacea purpurea or Usnea barbata (Old Man's Beard) within 2 weeks of enrollment~Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient's ability to tolerate protocol therapy, or that death within 7-10 days is likely~Previous hypersensitivity to alemtuzumab or its components~Potential subjects with cancer who are on active chemotherapeutic treatment or who take drugs with hematological effects will not be eligible~Current pregnancy, or unwilling to take oral contraceptives or refrain from pregnancy if of childbearing potential~Not able to understand the investigational nature of the study or give informed consent

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- Relapsed severe aplastic anemia (Type: EXPERIMENTAL): Subjects diagnosed with relapsed severe aplastic anemia
- Refractory severe asplastic anemia (Type: EXPERIMENTAL): Subjects diagnosed with refractory severe aplastic anemia
- Relapse after Alemtuzumab (Type: EXPERIMENTAL): Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 4-18years;~* Diagnosis of FD and IBS pain according to the Rome III criteria~* All parents or legal tutors must sign an informed consent document indicating their awareness of the investigational nature of this study.~Exclusion Criteria:~* Taking any other type of probiotic in the 2 months prior to enrollment~* Presence of intestinal motility disorders~* Presence of any other significant medical condition~* Presence of previous abdominal surgery~* Inability or unwillingness to give informed consent

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Mixture of three Bifidobacteria (Type: ACTIVE_COMPARATOR): Patients were administered 1 sachet per day of a mixture of three Bifidobacteria (namely, 3 billions of Bifidobacterium longum BB536®, 1 billion of Bifidobacterium infantis M-63®, and 1 billion of Bifidobacterium breve M-16V®) for six weeks. Subsequently, no preparation was administered for a 2-week-''washout'' period. At each follow-up visit subjects underwent a complete physical examination, data recorded on the daily diaries were collected and compliance to treatment was verified.
- Placebo (Type: PLACEBO_COMPARATOR): Patients were administered 1 sachet per day of placebo for six weeks. Subsequently, no preparation was administered for a 2-week-''washout'' period. At each follow-up visit subjects underwent a complete physical examination, data recorded on the daily diaries were collected and compliance to treatment was verified.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aerosolized Surfactant in Neonatal RDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants admitted to the NICU at Hutzel Women's Hospital (HWH)/Children's Hospital of Michigan (CHM)~2. Gestational age of 240/7-366/7 weeks~3. Postnatal age ≤ 24 hours~4. Clinical diagnosis of RDS based on (i) presence of at least two of the four classic symptoms (need of supplemental oxygen, tachypnea, intercostal retractions or grunting), and (ii) exclusion of other causes of respiratory failure and (iii) Clinician intent to administer surfactant if infant requires intubation~5. Respiratory support with NIV (CPAP or NIPPV or HFNC) with FiO2 ≥25% or PEEP ≥ 4 cmH20 or HFNC rate ≥ 2 LPM for ≤8 hours~6. Written informed consent from parent/guardian~Exclusion Criteria:~1. Previous receipt of surfactant~2. Infants with respiratory distress who are unstable and require immediate intubation~3. Active air leak syndrome (e.g. pneumothorax, pneumomediastinum)~4. Lethal congenital malformations; death anticipated within first 3 days of life; decision to withhold support~5. Serious abdominal, cardiac, airway or respiratory malformations including tracheal esophageal fistula, intestinal atresia, omphalocele, gastroschisis, pulmonary hypoplasia, or diaphragmatic hernia~6. Neuromuscular disorder resulting in respiratory compromise

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Hours
- Healthy Volunteers: f

Study Arms:
- Dose Schedule I (Type: ACTIVE_COMPARATOR): Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:1
- Dose Schedule II (Type: ACTIVE_COMPARATOR): Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:2
- Dose Schedule III (Type: ACTIVE_COMPARATOR): Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:1
- Dose Schedule IV (Type: ACTIVE_COMPARATOR): Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Biostate® in Children With Hemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects between 0 and \<12 years of age.~* Diagnosed with severe haemophilia A (FVIII:C \<1%), and pre-treated for a minimum of 20 to 50 exposure days.~* Have evidence of vaccination against hepatitis A and B (or presence of antibodies against hepatitis A and B due to either a previous infection or prior immunisation), as documented in the medical notes at enrolment.~* The subject and/or legal guardian understand(s) the nature of the study and has/have given written informed consent to participate in the study and is/are willing to comply with the protocol.~Exclusion Criteria:~* For all subjects at Day 1: Are actively bleeding.~* Have received an infusion of any FVIII product, cryoprecipitate, whole blood, plasma or desmopressin acetate in the 4 days prior to their dosing within the PK component.~* Have a known history of, or who are suspected of having FVIII inhibitors.~* Have received aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) within 7 days of administration of the IMP.~* Have an impaired liver function ie, bilirubin \>1.5 x upper limit of normal (ULN) and/or aspartate/alanine aminotransferase (AST/ALT) \>2.5 x ULN (referring to limits of the laboratory that performs the determination) at Screening.~* Are human immunodeficiency virus \[HIV\]-1/-2 antibody positive with a viral load of \>200/µL.~* Suffer from an acute or chronic medical condition, other than haemophilia A, which may, in the opinion of the Investigator, affect the conduct of the study.~* Suffering from von Willebrand disease (VWD) with von Willebrand factor: ristocetin cofactor (VWF:RCo) level \<50 IU/dL at Screening.~* Have a known or suspected hypersensitivity or previous evidence of severe side effects to a plasma-derived FVIII product or to human albumin.~* Have participated in a clinical study or used an investigational compound in another study (eg, a new chemical entity not registered for clinical use) in the 3 months preceding the first day of IMP administration, or are planning to enter such a study during the study period.~* Unwillingness and/or inability to comply with the study requirements.

- Gender: MALE
- Minimum Age: None
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Biostate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~Boys and Girls Age 9 to 15:~* Participant has not had sexual intercourse prior to the study and does not plan to become sexually active during the study period Day 1 to Month 7~Women Age 16 to 26:~* Participant has never had Pap testing or has had only normal results~* Participant has had 0 to 4 sexual partners at the time of enrollment~Exclusion Criteria:~Boys and Girls Age 9 to 15:~* History of allergic reaction that required medical intervention~* Currently enrolled in any other clinical study~* Participant is pregnant~* Participant is immunocompromised or has taken immunosuppressants in the last year~* Participant has received a marketed HPV vaccine or participated in an HPV vaccine clinical trial~* Participant has a history of positive test for HPV~Women Age 16 to 26:~* History of allergic reaction that required medical intervention~* Currently enrolled in any other clinical study~* Participant is pregnant~* Participant is immunocompromised or has taken immunosuppressants in the last year~* Participant has received a marketed HPV vaccine or participated in an HPV vaccine clinical trial~* Participant has a history of positive test for HPV~* Participant has a history of abnormal cervical biopsy result~* Participant has a history of external genital lesions

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- 9- to 15-Year-Old Females (Lot 1) (Type: EXPERIMENTAL): 9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
- 9- to 15-Year-Old Females (Lot 2) (Type: EXPERIMENTAL): 9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 2.
- 9- to 15-Year-Old Females (Lot 3) (Type: EXPERIMENTAL): 9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 3.
- 9- to 15-Year-Old Males (Lot 1) (Type: EXPERIMENTAL): 9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
- 16- to 26-Year-Old Females (Lot 1) (Type: EXPERIMENTAL): 9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Progesterone Effect on Individuals Diagnoses With AD and PTSD.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women ages 21 to 60;~2. Current diagnosis of AD and PTSD;~3. Drink regularly are not in an active phase of alcohol withdrawal;~4. Not at risk for suicide;~5. Not taking regularly psychoactive drugs including anxiolytics and antidepressants;~6. For women, have regular menses every 25-35 days.~Exclusion Criteria:~1. Current SCID diagnosis of any psychotic disorder;~2. Substance dependence (other than alcohol and nicotine) in the past 30 days;~3. Current unstable medical condition;~4. Positive test results at more than one baseline appointment on urine drug screens conducted for opiates, cocaine, marijuana, benzodiazepines, and barbiturates; for women, amenorrhea, use of oral contraceptives;~5. Known allergy to progesterone or peanuts (vehicle for micronized progesterone);~6. History of thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or Bleeding disorders, heart disease, diabetes or history of stroke.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Progesterone (Type: EXPERIMENTAL): For the three days prior to each test day every participant in this arm will receive one progesterone capsule (200 mg. bid) on the first day and 2 progesterone capsules per day for days 2 and 3. On the test day the participant will receive the last progesterone capsule (200 mg.bid). On the test day two scripts will be read one trauma related script (most traumatic experience) and one neutral script (relaxed scene given by participant)
- Placebo (Type: PLACEBO_COMPARATOR): For the three days prior to each test day every participant in this arm will receive one placebo capsule on the first day and 2 placebo capsules per day for days 2 and 3. On the test day the participant will receive the last placebo capsule. On the test day two scripts will be read one trauma related script (most traumatic experience) and one neutral script (relaxed scene given by participant)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, age above 36 months ;~* Adults, parent(s) or guardians are able to understand and sign informed consent for participation;~* Participants or guardians are able to attend all planned clinical appointment and obey and follow all study instructions;~* Infants no vaccinated with influenza or other preventive biologicals in recent 7 days;~* Axillary temperature ≤37℃.~Exclusion Criteria:~* Have medical record of participants or their family on allergy and egg, convulsion, falling sickness, encephalopathy and psychopathy;~* Low platelet or bleeding disorder do not allow vaccination into the muscle;~* Have damaged or lower immunological function;~* Received blood, plasma or immunoglobulin treatment since birth;~* Have inborn abnormality, develop obstacles or clinical diagnostic serious chronic ( Down Syndrome, diabetes, sickle cell anemia or neural Guillain-Barre Syndrome );~* Have or be doubtful of following diseases: respiratory system diseases, acute infection or active chronic, cardiovascular diseases, liver and kidney diseases, skin diseases, HIV.

- Gender: ALL
- Minimum Age: 36 Months
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Influenza Virus Vaccine (Type: EXPERIMENTAL): Influenza Virus Vaccine（no Preservative ) 0.5ml intramuscular injections
- Influenza Virus Vaccine(Preservative) (Type: EXPERIMENTAL): Influenza Virus Vaccine（add Preservative ) 0.5ml intramuscular injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) class I, II or III~* Undergoing thoracic surgery on an inpatient basis~* Age 18 up to 85 years of age~Exclusion Criteria:~* Subject is pregnant and/or lactating~* Subject has a serious Central Nervous System (CNS)pathology/trauma that, per clinical judgment of the investigator, precludes responsiveness or survival.~* Subject for whom alpha-2 agonists are contraindicated~* Subject meets any of the following cardiovascular criteria:~* Acute unstable angina (defined during current hospital stay)~* Suspicion of acute myocardial infarction.~* Considered to have a left ventricular ejection fraction of less than 30%.Decision to exclude is predicated in the Investigator's opinion, and may be based on any combination of acute presentations, recently preformed diagnostic studies, or a history that suggests poor cardiac function. Pulmonary congestion of a non-cardiac origin or mild congestive failure primarily attributable to etiologies other than poor ventricular function are not exclusion criteria.~* Subject has participated in a trial with any experimental drug within 30 days prior to enrollment in the study, or has ever been enrolled in this study.~* Subject is unable to undergo any procedures required by the protocol.~* Subject has acute hepatitis, a history or presence of chronic hepatitis, and /or has had a positive result for Hepatitis B surface antigen test.~* Subject requires dialysis (e.g., hemodialysis, peritoneal dialysis, CVVHD).~* Subject has a known, uncontrolled seizure disorder.~* Subject has a known psychiatric illness that could confound a normal response to sedative treatment.~* Subject is terminally ill with a life duration expectancy of \< 60 days.~* Subject has a history of Obstructive Sleep Apnea.~* Oxygen saturation is \< 90% on room air.~* Subject is on beta blocker medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Normal Saline (Type: PLACEBO_COMPARATOR): One group (placebo comparator) will receive a normal saline infusion, set at a rate as if it were the active drug.
- Dexmedetomidine (Type: ACTIVE_COMPARATOR): The second group (the study group) will receive a continuous infusion of dexmedetomidine titrated from 0.1 - 0.5 mics/kg/h to control pain for up to 24 hours after they are admitted to an open nursing unit after discharge from the PACU or ICU

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete